Trials / Completed
CompletedNCT02292186
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis Who Have Previously Received ALN-TTRSC
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Revusiran (ALN-TTRSC) |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2017-02-22
- Completion
- 2017-02-22
- First posted
- 2014-11-17
- Last updated
- 2020-07-09
- Results posted
- 2018-06-15
Locations
5 sites across 3 countries: United States, Canada, United Kingdom
Source: ClinicalTrials.gov record NCT02292186. Inclusion in this directory is not an endorsement.